Status:
COMPLETED
Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine.
Lead Sponsor:
Universidad Autonoma de San Luis Potosí
Conditions:
Migraine Headache
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Migraine is one of the three most disabling diseases worldwide. Constituted by recurrent episodes of headache, characterized by unilateral location, throbbing character, moderate or severe intensity, ...
Detailed Description
Migraine is a primary headache, currently one of the three most disabling diseases globally. It has an annual and lifetime prevalence of 18% and 33% in women, and 6 to 13% in men, respectively, with a...
Eligibility Criteria
Inclusion
- Men and women from 18 to 65 years old.
- Diagnosis of migraine according to the ICHD-III of the IHS at least one year before the study.
- You must have at least 4-14 migraine attacks per month.
- Not receiving prophylactic treatment for migraine
- Sign informed consent
Exclusion
- Pregnant or lactating patients.
- Patients with another type of non-migraine headache.
- Allergy to Sodium Valproate and/or Memantine
- Being a carrier of systemic disease (infectious, immunological, or metabolic processes) or cardiovascular (myocardial, coronary, or valvular disease) prevents their participation in the study.
Key Trial Info
Start Date :
February 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 15 2020
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT04698525
Start Date
February 15 2019
End Date
January 15 2020
Last Update
May 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Central Dr. Ignacio Morones Prieto
San Luis Potosí City, Mexico, 78290